## Acknowledgments

We graciously thank the patients and families who have donated their tumors to the Children's Brain Tumor Network and/or the Pacific Pediatric Neuro-oncology Consortium, without which, this research would not be possible. 
This work was funded through the Alex’s Lemonade Stand Foundation (ALSF) Childhood Cancer Data Lab (JNT, CSG, JAS, CLS, CJB, SJS), ALSF Young Investigator Award (JLR), ALSF Catalyst Award (JLR, ACR, PBS), ALSF Catalyst Award (SJS), ALSF CCDL Postdoctoral Training Grant (SMF), Children’s Hospital of Philadelphia Division of Neurosurgery (PBS and ACR), the Australian Government, Department of Education (APH), and NIH Grants 3P30 CA016520-44S5 (ACR), U2C HL138346-03 (ACR, APH), U24 CA220457-03 (ACR), and K12GM081259 (SMF).
This project has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003 (JLR, ACR, APH). 
The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government.

The authors would like to thank the following collaborators who contributed or supervised analyses present in the analysis repository that were not included in the manuscript: William Amadio, Holly Beale, Ellen Kephart, Alfred Lyle, and Olena Vaske.


## Author Contributions

|Author|Contributions|
|---|---|{% for author in manubot.authors %}
|{{author.name}}|{% for contribution in author.contributions %}{{ contribution }}{% if not loop.last %}, {% endif %}{% endfor %}|{% endfor %}


## Declarations of Interest

CSG's spouse was an employee of Alex's Lemonade Stand Foundation, which was a sponsor of this research.
JAS, CLS, CJB, SJS, and JNT are or were employees of Alex's Lemonade Stand Foundation, a sponsor of this research.

## Figure Titles and Legends
**Figure 1. Overview of the OpenPBTA project.**

## Table Titles and Legends
**Table 1. Molecular subtypes generated through the OpenPBTA project.**
Listed are broad tumor histologies, molecular subtypes generated, and number of specimens subtyped within the OpenPBTA project.

**Table 2. Patients with hypermutant tumors.**
Listed are patients with at least one hypermutant or ultra-hypermutant tumor.
Coding region TMB, phase of therapy, therapeutic interventions, cancer predispositions, and molecular subtypes are included.

